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Abstract 
Despite advances in understanding the pathophysiology of Fragile X syndrome (FXS), its            
molecular bases are still poorly understood. Whole brain tissue expression profiles have proved             
surprisingly uninformative. We applied single cell RNA sequencing to profile a FXS mouse model.              
We found that FXS results in a highly cell type specific effect and it is strongest among different                  
neuronal types. We detected a downregulation of mRNAs bound by FMRP and this effect is               
prominent in neurons. Metabolic pathways including translation are significantly upregulated          
across all cell types with the notable exception of excitatory neurons. These effects point to a                
potential difference in the activity of mTOR pathways, and together with other dysregulated             
pathways suggest an excitatory-inhibitory imbalance in the FXS cortex which is exacerbated by             
astrocytes. Our data demonstrate the cell-type specific complexity of FXS and provide a resource              
for interrogating the biological basis of this disorder. 
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 Introduction 
Fragile X syndrome (FXS) is the most common inherited form of intellectual disability and              
autism spectrum disorder (ASD). The disease results from the silencing of a single gene (​Fmr1 ​),               
which encodes the RNA-binding protein FMRP ​1​. The loss of FMRP leads to a              
neurodevelopmental disorder with an array of well characterized behaviour and cellular           
abnormalities, such as impaired cognitive functions, repetitive behaviours, altered synaptic          
morphology and function ​2​; many of which are reproduced in ​Fmr1 ​-KO mouse models ​3​.  
The molecular pathophysiology of FXS and FMRP function has been the subject of numerous              
studies over the past decades ​4,5​. The most extensively studied function of FMRP is its role as a                  
translational repressor. FMRP is critical to hippocampal long-term synaptic and spine           
morphological plasticity, dependent on protein synthesis. More specifically, the absence of FMRP            
leads to an exaggerated long-term synaptic depression, induced by the metabotropic glutamate            
receptor 5 (mGLUR5-LTD) ​6​. However, several ambitious clinical trials that aimed to suppress             
translation or inhibit mGluR pathways have thus far failed ​7​. The significance of FMRP’s role as a                 
translation repressor at synapses is not without challenges. First, only a few mRNAs that are               
bound by FMRP showed a consistent increase in protein levels upon loss of FMRP, and increased                
levels of proteins are not always pathogenic ​8​. More importantly, focusing on FMRP’s             
translational function in dendritic synapses overlooks the fact that the great majority of this              
protein is located in the cell soma ​9​. Indeed, a wide range of research has associated FMRP to                  
multiple steps of the mRNA life cycle, including pre-mRNA splicing ​10​, mRNA editing ​11,12​, miRNA               
activity ​13,14​, and mRNA stability ​15,16​. Additionally, FMRP may function outside the RNA-binding             
scope, by chromatin binding and regulating genome stability ​17,18​, as well as directly binding to               
and regulating ion channels ​19,20​.  
Most of the above-mentioned studies focus on FMRP’s function in neurons, and rightly so, as               
neurons have the highest FMRP protein levels in the brain ​9​. Evidence from clinical studies with                
FXS patients and from mouse models of the disease supports the view that neurons are the main                 
affected cell type ​21,22​. However, to add to the complexity, this is not to say that the other cell                   
types in the brain do not express FMRP or are not affected upon loss of it. Indeed, astrocytes,                  
oligodendrocyte precursor cells, and microglia express FMRP in a brain structure and            
development-dependent manner ​23​. FMRP-depleted astrocytes are more reactive ​24​, and their           
deficits alone may account for some of the phenotypes seen in Fragile X neurons particularly               
during development ​25–28​. 
This profound body of work over decades has collectively pieced together a complex picture for               
FMRP’s functions. However, this also poses a challenge to building an overview of the molecular               
impact of Fragile X. Here we present our effort to bridge this gap using an unbiased approach to                  
survey the Fragile X brain. We took advantage of the power of single cell RNA-seq to determine                 
which cells are affected at an early postnatal development stage, using the transcriptome as a               
sensitive reflection of the cellular status.  
We profiled the transcriptome of over 18,000 cells from the cerebral cortex of wild type (WT)                
and ​Fmr1 ​-knock out mice (​Fmr1 ​-KO) at postnatal day 5. Our findings present new insights into               
the cell type specific consequences of FXS. We detected a heterogeneity in the response of               
different cell types to the loss of FMRP. We find in particular a higher impact on the expression                  
of mRNAs previously identified as FMRP binding targets in the brain (Darnell et al 2011), and we                 
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 show that this effect is prominent in neurons compared to other cells. We detect a divergent                
response of pathways downstream of mTOR signaling across different neuron subtypes, which            
suggests that excitatory neurons do not display a hyperactivation of this pathway. Taken             
together with the observed dysregulation of synaptic genes in astrocytes as well as neurons, our               
results suggest an impact in cell-cell communication that can result in a cortical environment of               
greater excitability. 
Cell type proportions are not impacted in the neonatal ​Fmr1​-KO cortex 
To capture early molecular events in the Fragile X syndrome, we performed single cell RNA-seq               
using the InDrop system ​29​, from the cortex of both ​Fmr1 ​-knock out (​Fmr1 ​-KO) and wild type                
(WT) FVB animals at postnatal day 5 (P5, Figure 1a, Methods), a critical period in cortical                
development for neuronal and synaptic maturation ​30–32​. After stringent filtering, we obtained            
18,393 cells for which we detected an average of 1,778 genes and 3,988 transcripts (see               
Methods). After unbiased clustering we classified these cells into seven major cell types, with              
specific expression of established markers ​33–36​ (Figure S1a; Methods).  
Figure 1 
 
We did not detect a genotype bias in the clustering (Figure S1b). Additionally, all major cell types                 
were detected in both ​Fmr1 ​-KO and WT animals, with consistent proportions across individual             
mice (Figure S1c), indicating that ​Fmr1 ​-KO mice do not have large scale cell differentiation              
deficits at this stage, consistent with previous reports ​9​. To better dissect the effect of FMRP loss                 
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 on different cell types, we independently re-clustered the broad cell types. We identified a total               
of 18 distinct populations (Figure 1b, S1d-g; Methods). These populations include vascular cells             
(endothelial cells and pericytes), fibroblasts, ependymal cells, different neuron subtypes and           
glial cells (Figure 1b). Neuron clusters were classified as excitatory neurons (Figure S1d,             
Excitatory, ​Nrgn ​+ Lpl​+ Slc17a6 ​+ ​), immature interneurons (Figure S1d, Interneuron: ​Gad1 ​+ Dlx1 ​+           
Htr3a​+ ​), ganglionic eminence inhibitory precursors (Figure S1d, Ganglionic: ​Ascl1 ​+ Dlx2 ​+ Top2a​+ ​),           
Cajal Retzius cells (Figure S1d, CR: ​Reln ​+ Calb2 ​+ Lhx5 ​+ ​) and subventricular zone migrating             
neurons (Figure S1d, SVZ: ​Eomes​+ Sema3c​+ Neurod1 ​+ ​). We detected two immature astrocyte            
populations, including a small group with markers of reactive astrocytes (Figure S1e,            
Astrocytes_1: ​Aqp4 ​+ Aldoc​+ Apoe​+ ​; Astrocytes_2: ​Ptx3 ​+ Igfbp5 ​+ C4b​+ ​). Immune cells detected           
consist largely of microglia (Figure S1f, Microglia: ​Cx3cr1 ​+ P2ry12 ​+ Csf1r ​+ ​), but we also identified              
small clusters of T cells (Figure S1f, T Cells: ​Cd3d​+ Ccr7 ​+ Cd28 ​+ ​), border macrophages (Figure S1f,                
Border Macrophages: ​Lyz2 ​+ ​Msr1 ​+ ​Fcgr4 ​+ ​) and a population of microglia-like cells marked by             
high expression of Ms4a cluster genes (Figure S1f, Microglia Ms4a+: ​Ms4a7 ​+ ​Ms46b​+ ​Mrc1 ​+ ​). The              
initial clusters containing oligodendrocytes were classified as mature oligodendrocytes (Figure          
S1g, Oligodendrocytes: ​Mbp​+ Sirt2 ​+ ​Plp1 ​+ ​), oligodendrocyte progenitor cells (Figure S1g, OPC:           
Pdgfra​+ ​ Olig2 ​+ ​ Sox10 ​+ ​) and a small group of neural stem cells (NSC: ​Btg2 ​+ ​ Dll1 ​+ ​ Dbx2 ​+ ​). 
Loss of FMRP results in small expression changes across a broad spectrum of             
processes 
We examined differential expression between ​Fmr1 ​-KO and WT mice for each cell type             
identified. In total, we identified 1470 differentially expressed (DE) genes (FDR < 0.01 and fold               
change >= 1.15x) in one or more cell types (Figure S2a-b; Table S1). The majority of DE genes                  
showed small fold changes (mean fold change = 1.3x). The effect of FMRP loss seems drastically                
different across cell types as most differentially expressed genes were found in neurons and              
endothelial cells (Figure S2a). This result does not seem to be dependent on statistical power,               
given that the number of DE genes detected did not correlate to the number of cells available for                  
different cell types.  
Given the broad but low effect size resulting from loss of FMRP, we focused on quantifying the                 
impact on annotated pathways. To this end, we performed a gene set enrichment analysis              
(GSEA; see Methods). Consistent with the larger effect observed using differential gene            
expression analysis, most significantly dysregulated processes are also found in neurons, further            
suggesting that neurons are the cells most impacted by FMRP loss (Figure 2a-b, Figure S2c-d,               
Table S2).  
We find that metabolic processes are upregulated in most FMRP deficient cell types (e.g.              
Translation, Ribosome, Respiratory Chain Complex and Oxidative Phosphorylation).        
Translational processes are significantly upregulated in neurons, vascular cells (endothelial and           
pericytes), oligodendrocytes and OPCs. However, upregulation is clear in most cell types even             
when the difference did not reach a significant level (Figure 2c). Similarly, mitochondrial             
pathways are some of the most strongly upregulated processes in multiple cell types including              
OPCs, oligodendrocytes, endothelial cells and pericytes (Figure 2d). Transcriptional activation of           
genes involved in ribosome biogenesis ​37 as well as oxidative phosphorylation ​38 are known              
downstream effects of the mTOR pathway. This upregulation across multiple cortical cell types             
is in agreement with previous reports of elevated phosphorylation of mTOR in ​Fmr1 ​-KO mice              
39,40​, and subsequent increase in signalling through the mTOR complex 1 pathway. The increased              
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 abundance of mRNAs for translation related factors in all cortical cell types also agrees with the                
well established impact of FMRP on protein synthesis ​39,41​.  
Figure 2 
 
On the other hand, there is a common trend of downregulation across many cell types for genes                 
involved in synaptic signaling, vesicle transport and ion homeostasis (Figure 2e). Most of these              
processes are significantly downregulated in neurons and OPCs, and include common           
downregulated genes (e.g. Apoe, Sar1b, Clstn1, Rab5a and Sqstm1 involved in vesicle pathways),             
suggesting that intracellular transport of molecules is impaired in multiple cell types. Synaptic             
signaling and cell surface proteins notably respond differently in astrocytes, and are discussed             
below. 
Taken together, this reveals a transcriptional landscape in the neonatal ​Fmr1 ​-KO cortex where             
not all cell types are affected equally. Most genes are differentially expressed in a cell type                
specific manner, however they are often involved in related processes across cell types. There is               
excessive expression of factors involved in biomolecule production (protein and ATP synthesis)            
in multiple cell types. Conversely, there is insufficient expression of factors important for             
developing cellular communication and maintaining ion homeostasis in multiple cell types,           
particularly in neurons (Figure 2e). These related processes that are impacted in multiple cell              
types in the ​Fmr1 ​-KO cortex collectively point to enhanced growth and metabolism while             
suggesting hindered or delayed network development through impaired cell-cell         
communication. 
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 Multiple pathways display opposite effects in astrocytes and neurons and          
suggest hyperexcitability 
We detect many processes where neurons and astrocytes show opposite effects, revealing a             
surprisingly different impact of the loss of FMRP in these two cell types. Genes encoding for                
synaptic signaling and cell surface proteins are in general downregulated in neurons and other              
cell types, while upregulated in astrocytes (Figure 3a). The main dysregulated genes in these              
processes include a large number of known receptor-ligand pairs involved in cross-cell signaling             
and their dysregulation could contribute to an imbalanced extracellular neuro and           
gliotransmitter homeostasis (Figures 3b-c; leading edge analysis, GSEA). Upregulated genes in           
astrocytes contributing to this enrichment include ephrin and GABA receptors as well as other              
solute carriers. Related genes, however, are downregulated in neurons. For example, we            
detected a downregulation of Efna5 and Epha7 in ​Fmr1 ​-KO neurons, both critical to cortex              
development and plasticity and involved in the establishment of corticothalamic projections           
42–44​. This downregulation could therefore be involved in the deficit of cortical-subcortical            
circuits reported in individuals with FXS ​45​. Conversely, we observed an upregulation of Ephb3              
and Epha4 receptors in astrocytes, which are activated by ephrin-B produced by neurons             
(Figure 3b). Activation of these receptors leads to enhanced release of D-serine (NMDA receptor              
coagonist) and glutamine (uptaken by excitatory terminals and converted to glutamate)​46,47​.           
Similarly, we detected a downregulation of Slc1a4 (Asct1) in neurons, which could also             
contribute to reduced clearance of D-serine ​48​.  
Figure 3  
 
Further, we observed an upregulation of Gabbr1 and Gabbr2 in ​Fmr1 ​-KO astrocytes, suggesting             
enhanced glutamate release resulting from the activation of GABA​B receptors (Figure 3b) ​
49​.             
Other genes that could lead to enhanced clearance of GABA and glycine (both inhibitory              
neurotransmitters) from the neuronal environment are also upregulated in astrocytes, such as            
Slc6a1 (GAT-1), and Slc6a9 (GlyT-1) (Figure 3c). Our data also suggest a reduced sensitivity to               
environmental GABA inhibitory signals in neurons, which show downregulation of a GABA​A            
receptor gamma subunit (Gabrg2). Previously, in both fly and mouse models of FX, multiple              
subunits (including gamma) were reported to have reduced expression ​50​. We additionally            
detected reduced expression of Slc12c5 (KCC2) in ​Fmr1 ​-KO neurons, a transporter crucial for             
the switch of GABA from being excitatory to inhibitory ​51​, which could underlie the delayed               
switch in GABA polarity seen in ​Fmr1 ​-KO mice ​52​. Collectively, these changes point to an               
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 imbalanced extra and intra-neuronal environment that favors excitation over inhibition (Figures           
3b-c). Indeed, cortical hyperexcitability is believed to be the biological basis of ASD and epilepsy,               
including FXS​53​.  
Several other observed examples of dysregulated solute carriers in multiple cell types may             
contribute to the FXS phenotypes of mRNA translation defects and autistic behaviors through             
pathways other than regulation the glio and neurotransmitters as discussed above. These            
include genes downregulated in oligodendrocytes, such as Slc1a2 (GLT-1), involved in glutamate            
regulation and critical for white matter development ​54,55​, or downregulated in endothelial cells,             
such as Slc7a5 (LAT-1), a mediator of amino acid uptake which can impact the amino acid profile                 
and mRNA translation in the brain, causing neurological abnormalities ​56​. Astrocytes in turn,             
show an increased expression of Slc30a10 (ZnT10), responsible for Zn​2+ and Mn​2+ transport to              
the extracellular space ​57​. High cellular levels of Zn​2+ and Mn​2+ in turn induce the transcription of                 
metallothioneins ​58​. We observed upregulation of Slc30a10 in astrocytes, which would predict            
downregulation of metallothioneins. Indeed, Mt1 and Mt2 are among the most strongly            
downregulated genes in astrocytes (Figure S2b). Metallothioneins play a role in the protection of              
the central nervous system in response to injury, and neuronal recovery is impaired in their               
absence ​59​.  
Our data points to a picture in which cell types are impacted widely in different and sometimes                 
compensatory ways, and these expression changes are moderate. This may explain why previous             
whole brain and whole cortex assays have provided underwhelming insights. The ability to have              
a cell type specific expression profile highlights the wide range of the effects of FMRP loss that                 
result in strong pathology. 
FMRP loss impacts neuronal homeostasis 
A total of 473 categories (88%) were affected in neurons (Figure 2a-b, S2c-d). We found that the                 
main neuron-specific upregulated processes correspond to RNA splicing, DNA binding and           
chromatin organization (Figure 4a). Upregulated genes in RNA splicing categories encode core            
spliceosomal proteins ​60​, including RBM39, Snrnp200, Hnrnpn, Srsf3 and Srsf4. Upregulation of            
these factors has been previously linked to an increased rate of proliferation ​61–63​. Similarly, the               
most strongly upregulated genes associated with DNA binding, chromatin and other significant            
transcriptional regulation terms include many regulators of proliferation (Hmgb2, Top2a, Mcm7,           
Pcna) and of neuron differentiation (Insm1, Dlx2, Tead1, Tshz1, Tcf12) ​64–66​. 
Figure 4 
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 More categories are specifically downregulated in neurons (n=245, 51%), which include           
functions related to synaptic and membrane components, ion channels and neuron projections            
(Figure 4b). This broad impact in synaptic processes is consistent with the idea that FXS is a                 
neuronal disorder that results from a suboptimal balance in connectivity ​67​. The top             
downregulated genes related to synapses and neuronal projections (Figure 4c) include Vamp2, a             
key component of synaptic vesicle trafficking ​68​; Camkk2 and Camk2b, which are both involved              
in the formation of dendritic spines ​69​; and Grm5, which encodes for the mGluR5 receptor, and                
noticeably is one of the main proposed therapeutic targets for FXS ​70​. Reduced abundance of               
these and other synaptic and neuronal projection related mRNAs reveals multi-leveled           
transcriptome deficits (vesicle transport, cell morphology and receptors, affecting both pre and            
postsynaptic structures), which could be behind the known deficits of FXS neurites and synaptic              
development ​4​. 
FMRP bound mRNAs are downregulated in ​Fmr1​-KO neurons 
FMRP binds directly hundreds of mRNAs identified in the mouse brain ​71–73 or in cell lines ​74,75​.                 
The current model suggests that FMRP binding leads to translational repression of its bound              
mRNAs (Darnell 2011, Chen et al 2014), although this repression was only validated for a               
handful of direct targets ​8​. We focused on the impact of FMRP loss on mRNA abundance of its                  
direct binding targets. Out of the 842 mRNAs bound by FMRP in the mouse brain ​72​, we detected                  
839 expressed by at least one cell type in our data. We compared the fold change between                 
Fmr1 ​-KO and WT for FMRP bound mRNAs to all other expressed. Consistent with the strong               
effect of FMRP loss in neurons, FMRP bound mRNAs show a stronger downregulation in neurons               
compared to other expressed mRNAs (p < 10​-57​, Wilcoxon rank-sum), while for other cell types               
there is little difference (Figure 5a, S3a).  
Figure 5 
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 This steeper downregulation of FMRP bound mRNAs in neurons could result from higher             
expression levels of these mRNAs in neurons. To determine that, we examined the cell type               
specificity of expression for the FMRP bound mRNAs (Figure 5b). A large fraction (35%) of these                
mRNAs are in fact most abundant and most affected in neurons (cluster 1, Figure 5b-c, S3c-d).                
However, abundance does not seem to be critical for FMRP effect: a clear set of 34% of FMRP                  
bound mRNAs are most abundant in non-neuronal cell types, but their downregulation is             
strongest in neurons (cluster 2, Figure 5b-c, S3c-d). The impact on FMRP bound gene expression               
may be further mediated by cell type specific expression of protein partners of FMRP ​5,76​, several                
of which are RNA binding proteins themselves. Many of these binding partners have functions in               
processes impacted in neurons or multiple cell types, such as splicing, cell signaling, vesicle              
transport and translation ​76​. We find no clear difference at RNA levels that suggests these genes                
contribute to the neuron-specific bound mRNA downregulation. Most FMRP binding partners           
are expressed at higher levels in neurons, oligodendrocytes and OPCs (Figure 5d). Taken             
together, this suggests that the neuron-specific effect likely results from the predominant            
expression of FMRP in neurons, previously shown by multiple immunostaining studies ​9,23,77,78​.            
We did not detect any difference in ​Fmr1 expression across WT cells of different cell types                
(Figure S3b), which suggests the existence of a translational control mechanism behind FMRP             
levels in different cell types. 
In conclusion, we find that FMRP bound mRNAs are preferentially downregulated in neurons,             
which are known to express higher levels of FMRP, and that this effect is also associated with the                  
specificity of target mRNA expression. 
Neuron subtypes respond differently to the loss of FMRP 
Many synaptic pathways are collectively impacted in ​Fmr1 ​-KO neurons, as described above. We             
then examined if these and other pathways are uniformly or differently impacted in neuron              
subtypes. We focused on the three most abundant neuron subtypes: excitatory, interneurons            
and ganglionic eminence progenitors (Figure S1d). Indeed, we observed a common           
downregulation trend across most of the neuronal projection and synaptic pathways (Figure 6a). 
However, we detected little overlap in the top dysregulated gene sets in these subtypes (Figure               
6b). Firstly, we found that the increased expression of genes related to ribosomes and              
translation is unique to interneurons. In fact, excitatory neurons show the reverse trend, with              
downregulation of these genes (Figure 6c). Secondly, mitochondrial pathways are also affected            
in opposite ways in different neuronal subtypes. They are downregulated in excitatory neurons             
while upregulated in interneurons and ganglionic progenitors (Figure 6d). This reveals a critical             
difference in the effect of FMRP loss on different neuronal subtypes. It has been observed that                
mTOR signaling is increased in ​Fmr1 ​-KO mice ​39,40 as well as in humans with FXS ​79​. As                 
mentioned previously, mTOR signaling results in increased metabolic activity and, in particular,            
in upregulation of translation activity (and ribosomal genesis) as well as in upregulation of              
mitochondrial processes ​37,38​. We observe such an increase only in inhibitory neurons, suggesting             
that they are the subtype affected by the hyperactivation of mTOR signaling. On the other hand,                
the downregulation of these pathways in excitatory neurons suggests that in this subtype there              
is a previously underappreciated dampening of mTOR activity. 
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 Figure 6 
 
Lastly, the top downregulated genes in interneurons are enriched for genes involved in             
pathways such as neuron maturation (GO:0042551, p<0.001, hypergeometric; e.g. App, Nrxn1)           
and synaptic vesicle localization (GO:0097479, p<0.01, hypergeometric; e.g. Adcy1, Apba1 and           
Syn2), which tend to be higher expressed at later stages of neuronal development ​80–83​.              
Conversely, top downregulated genes in excitatory neurons (other than ribosomal and           
mitochondrial related genes), include many regulators of early stage neurogenesis (e.g. Slc1a3,            
Vcan, Tpi1, Vim, Lrrc17, Sox9 and Ppap2b) ​84–88​. The contrasting natures of genes that are most                
downregulated in excitatory versus inhibitory neurons (neurogenesis vs neuron maturation),          
together with the opposite responses of the ribosomal and translational genes, which decrease             
with neuron differentiation ​89​, may reveal a misalignment of developmental progress between            
these two major neuronal subtypes. This misalignment may contribute to the           
excitatory-inhibitory imbalance proposed for FXS and other autism disorders ​90​. 
Discussion 
Our study presents the first attempt to dissect the cell type specific contributions to FXS               
pathology using the power of single cell RNA-Seq, and reveals cell type specific alterations that               
could be masked in global measurements. We found that FMRP loss results in overall small               
changes to individual gene expression, however there is a broad misregulation of functionally             
related genes. We have described several novel findings resulting from the ability to dissect cell               
type specific effects in the FX mouse model including: i) Higher impact of FMRP loss in neurons;                 
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 ii) Changes in abundance of cell-cell signalling genes that could increase environmental            
excitability; iii) Potential differences in mTOR activity across different cell types. We further             
discuss these findings below. 
Neurons are markedly the most impacted cell type, and the processes associated with             
downregulated genes encompass critical functions for neuronal development, function and          
morphology. Neurons are also the only cell type where the set of mRNAs bound by FMRP in the                  
mouse brain are distinctively downregulated. Recent evidence suggests that the degradation           
rates of FMRP bound mRNAs are higher in ​Fmr1 ​-KO neurons, which results in their decreased               
abundance ​16​. The same post-transcriptional mechanism is likely behind the lower mRNA            
abundances detected in our single cell analysis and further strengthens the role of FMRP in the                
regulation of mRNA stability, possibly coupled to the regulation of translation rates ​91​. 
A growing body of evidence supports the role of astrocytes in the pathology of neurological               
disorders ​92,93​. Astrocyte involvement in FXS in particular was previously demonstrated by            
co-culture studies where neurons exhibited decreased levels of synaptic proteins and abnormal            
dendritic morphology when grown with astrocytes from FXS mice ​94​. Our analysis of the              
Fmr1 ​-KO single cell transcriptome reveals that many key receptors and secreted proteins are             
misregulated in astrocytes. These alterations suggest that ​Fmr1 ​-KO astrocytes contribute to an            
environment of increased excitability, and could also impact neuronal development. 
Multiple cell types display an upregulation of genes involved in translational and energy             
production processes, which are likely a downstream consequence of the increase in mTOR             
complex 1 signaling that has been previously detected in ​Fmr1 ​-KO mice. The activation of this               
pathway is thought to be linked to the exaggerated mGluR5-LTD and a critical mechanism              
behind FXS pathology ​39,95​. Surprisingly, we find that cortical excitatory neurons in fact show an               
opposite downregulation trend for both types of processes, indicating that they respond to the              
loss of FMRP differently than inhibitory neurons and possibly are reflecting a decrease in mTOR               
activity. Indeed, stimulation of the N-methyl-D-aspartate receptor (NMDAR) decreases mTOR          
signaling activity ​96–98​. We find that NMDAR subunits are most highly expressed in excitatory              
neurons (Figure S4a). Further, we also find upregulation of one NMDAR subunit (Grin2b)             
specifically in ​Fmr1 ​-KO excitatory neurons (Figure S4b, FDR=0.019). This increased expression           
of NMDAR in excitatory neurons, together with a glio and neurotransmitter environment that             
favors activation of NMDAR (Figure 3b-c), likely results in increased NMDAR signalling which             
suppresses mTOR activity and downstream pathways in excitatory neurons. On the other hand,             
inhibitory neurons exhibit increased metabolic gene expression which is concordant with mTOR            
hyperactivity. This implies that the current therapeutic strategies which propose components of            
the mTOR signaling pathway as targets for rescuing the cognitive and synaptic deficits in FXS               
have to consider that the outcome may be drastically different across neuron subtypes. 
Finally, many of the neuronal downregulated pathways including neuron projection terms and            
vesicle transport were identified as downregulated both in RNA and protein levels by recent              
studies in human ​in-vitro neurons derived from embryonic or pluripotent stem cells ​99–101​. This              
suggests that the downstream molecular consequences of the absence of FMRP in neurons are              
well conserved and that the wealth of altered pathways we observed in the ​Fmr1 ​-KO mouse               
model can provide a valuable resource for future studies in FXS patients and the design of                
therapeutic approaches. 
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 Figure Legends 
Figure 1 
Cortical cell types in ​Fmr1​-KO and WT mice  
a) ​Overview of the sample collection b) tSNE representation of cells colored by cell type (top)                
and colored by expression level of example maker genes (bottom).  
Figure 2 
Misregulated Gene Ontology categories per cell type reveal higher impact in ​Fmr1​-KO            
neurons  
a-b) ​Comparative diagram of upregulated (a) or downregulated (b) GO categories in neurons             
and other cell types. Keywords and terms from the top enriched GO categories for each ontology                
are shown. ​c-d) ​Comparison of normalized enrichment scores (NES) across cell types for GO              
terms involved in translational (c: e.g. Ribosome, GO:0005840; Translation, GO:0006412) or           
mitochondrial (d: e.g. Respiratory chain, GO:0070469; ATP synthesis = ATP synthesis coupled            
electron transport, GO:0042773) processes. ​e) ​Summary diagram of enriched processes (dark           
red/blue; FDR<0.01) and trends (light red = NES>1, FDR<0.3; light blue = NES<-1, FDR<0.3) in               
other cell types. 
Figure 3 
Dysregulated genes in ​Fmr1​-KO astrocytes and neurons involved in synaptic functions 
a) Comparison of normalized enrichment scores (NES) across cell types for all GO terms that               
show opposite signals in astrocytes and neurons (e.g. Int. synaptic membrane = Integral             
component of synaptic membrane, GO:0099699; Int. plasma membrane = Intrinsic component of            
plasma membrane, GO:0031226). ​b-c) ​Summary diagram of strongest dysregulated genes in           
astrocytes and neurons involved in synaptic signaling and regulation which suggest an increased             
release of excitatory (b) and a higher clearance of inhibitory (c) glio and neurotransmitters in               
the synaptic environment. D-Ser = D-Serine; GABA = Gamma aminobutyric acid; Gln = Glutamine;              
Glu = Glutamate; Gly = Glycine. 
Figure 4 
FMRP loss impacts neuronal homeostasis 
a) ​Example neuron-specific upregulated gene groups: DNA binding (GO: 0003677; top), and            
chromatin (GO:0000785; bottom). ​b) ​Example neuron-specific downregulated gene groups:         
synaptic membrane (GO:0097060; top) and axon (GO:0030424; bottom). ES = GSEA Enrichment            
Score. NES = GSEA Normalized Enrichment Score. ​c) ​Expression in all neuronal cells for example               
genes downregulated in ​Fmr1 ​-KO involved in synaptic and neuron projection processes. 
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Figure 5 
FMRP bound mRNAs show greater downregulation in neurons 
a) ​Cumulative distribution plot of the log2 fold change between ​Fmr1 ​-KO and WT gene              
expression in neurons. Dashed lines represent mRNAs annotated as FMRP bound by Darnell et              
al. expressed in that cell type. Full lines represent all other expressed genes in that cell type. b)                  
Heatmap of expressed FMRP bound mRNAs in WT cortex cells. Genes were clustered based on               
their expression pattern across cell types and resulting clusters comprise genes expressed at             
higher levels in neurons (cluster 1), non-neuronal cell types (cluster 2) and without cell type               
specificity (cluster 3). ​c) ​Cumulative distribution plot of the log2 fold change between ​Fmr1 ​-KO              
and WT gene expression in neurons. Colored lines represent each specific subset of expressed              
genes: Neuron FMRP bound mRNAs, which show highest expression in neurons (blue, cluster 1,              
Figure 5b); Non-neuronal FMRP bound mRNAs, which show highest expression in other cell             
types (pink, cluster 2, Figure 5b); Non-specific FMRP bound mRNAs (grey, cluster 3, Figure 5b),               
which are expressed at similar levels by all cortical cell types; and all other mRNAs expressed in                 
neurons (black). ​d) ​Expression levels of known protein binding partners of FMRP across cell              
types. Aggregated bulk values were calculated per cell type (UMIs per million) . 
Figure 6 
Neuron subtypes show diverse misregulated genes 
a) ​Comparison of normalized enrichment scored (NES) across neuron subtypes for synaptic            
related GO terms (e.g. Synaptic plasticity = Regulation of synaptic plasticity, GO:0048167;            
Postsynaptic receptors = Regulation of postsynaptic membrane neurotransmitter receptor         
levels, GO:0099072). ​b) ​Overlap of top 5% upregulated (red) or downregulated (blue) genes in              
neuron subtypes. ​c-d) ​Comparison of normalized enrichment scores (NES) across neuron           
subtypes for translation related GO terms (c: e.g. Ribosome, GO:0005840; Translation,           
GO:0006412) or mitochondrial function related GO terms ​(d: e.g. Respiratory chain,           
GO:0070469; Oxidoreductase activity, GO:0016491). 
Figure S1 
a) ​tSNE representation of cells colored by major cell type. ​b) tSNE representation of cells colored                
by genotype. ​c) Cell type composition of each collected sample. ​d-g) Unbiased sub-clustering             
results and subtype identification for each of the main cell types: ​d) Neurons; ​e) Astrocytes; ​f)                
Microglia and other immune cells; ​g) ​ Oligodendrocytes and OPCs. 
Figure S2 
a) ​Differentially expressed (DE) genes identified per cell type. ​b) ​Plot of the log2 fold change                
(logFC) for each gene per normalized expression in aggregated WT cells (UMIs per million). c-d)               
UpSetR diagrams showing overlap between GO terms identified as significantly upregulated (c)            
or downregulated (d)​. 
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 Figure S3 
a) Cumulative distribution plot of the log2 fold change between ​Fmr1 ​-KO and WT gene              
expression in each cell type. Dashed lines represent genes annotated as FMRP bound by Darnell               
et al. expressed in that cell type. Full lines represent all other expressed genes in that cell type.                  
b) ​Fmr1 expression (UMIs) in WT cells of each cell type. ​c) ​Aggregated expression (UMIs per                
million) in WT cells for each cell type of all FMRP bound genes that are classified as neuronal                  
(cluster 1), non-neuronal (cluster 2), or non-specific (cluster 3) in terms of their pattern of               
expression (heatmap clusters, Figure 5b). d) Cumulative distribution plot of the log2 fold change              
between ​Fmr1 ​-KO and WT gene expression in each cell type. Colored lines represent each              
specific subset of expressed genes genes: Neuronal FMRP bound mRNAs, which show highest             
expression in neurons (blue, cluster 1, Figure 5b); Non-neuronal FMRP bound mRNAs, which             
show highest expression in non-neuronal cell types (pink, cluster 2, Figure 5b); Non-specific             
FMRP bound mRNAs (grey, cluster 3, Figure 5b), which are expressed at similar levels by all                
cortical cell types; and all other mRNAs expressed in neurons (black). 
Figure S4 
a) tSNE representation of neurons colored by expression level of NMDAR subunits detected,             
Grin1 (left) and Grin2b (right). ​b) Expression level (normalized UMIs) in ​Fmr1 ​-KO or WT              
excitatory neurons for Grin2b. 
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 Methods 
Mice 
Wild type (WT; FVB.129P2-​Pde6b​+ Tyr ​c-ch ​/AntJ; JAX stock 004828) and ​Fmr1 knockout           
(​Fmr1 ​-KO; FVB.129P2-​Pde6b​+ Tyr ​c-ch ​Fmr1 ​tm1Cgr ​/J; JAX stock 004624) mice at postnatal day 5 (P5)             
of both sexes were used. All experimental procedures followed the animal care protocol             
approved by the University of Massachusetts Medical School Institutional Animal Care and Use             
Committee (IACUC). 
Cortex dissection and dissociation 
Three mice per genotype were used for single-cell collection. P5 mice were euthanized by              
decapitation and the brain was rapidly removed and placed in cold dissection buffer (1x HBSS).               
The brain was rapidly dissected to collect the cerebral cortex (both hemispheres) and the tissue               
was dissociated using the Papain dissociation system (Worthington Biochemical) following the           
manufacturer’s protocol with a 30 minute incubation. 
InDrop collection and scRNASeq library preparation 
Dissociated cortical cells were resuspended in PBS, filtered through a 70 micron cell strainer              
followed by a 40 micron tip strainer, and counted with a Countess instrument (Life              
Technologies). The cells were further diluted to the final concentration (80,000 cells/mL) with             
OptiPrep (Sigma) and PBS, and the final concentration of OptiPrep was 15% vol/vol. A total of                
2,000 to 5,000 cortical cells were collected per mouse and processed following the InDrop              
protocol ​29,102​. Final libraries containing ~1,200 cells were constructed and sequenced on an             
Illumina NextSeq 500 instrument, generating on average ~130 million reads per library (Table             
S3). 
Data processing 
Cleanup, alignment and transcript quantification 
Sequencing reads were processed as previously described ​103 and the pipeline is available             
through GitHub (github.com/garber-lab/inDrop_Processing). Briefly, fastq files were generated        
with bcl2fastq using parameters --use-bases-mask y58n*,y*,I*,y16n* --mask-short-adapter-reads 0        
--minimum-trimmed-read-length 0 --barcode-mismatches 1. ​Valid reads were extracted using the          
barcode information in R1 files and were aligned to the mm10 genome using TopHat v2.0.14               
with default parameters and the reference transcriptome RefSeq v69. Alignment files were            
filtered to contain only reads from cell barcodes with at least 1,000 aligned reads and were                
submitted through ESAT (github.com/garber-lab/ESAT) for gene-level quantification of unique         
molecule identifiers (UMIs) with parameters ​-wLen 100 -wOlap 50 -wExt 1000 -sigTest .01             
-multimap ignore -scPrep​. Finally, we identify and correct UMIs that are likely a result of               
sequencing errors, by merging the UMIs observed only once that display hamming distance of 1               
from a UMI detected by two or more aligned reads. 
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 Dimensionality reduction and clustering 
Gene expression matrices for all samples were loaded into R (V3.6.0) and merged. Barcodes              
representing empty droplets were removed by filtering for a minimum of 700 UMIs observed.              
The functions used in our custom analysis pipeline are available through an R package              
(github.com/garber-lab/SignallingSingleCell). Using the raw expression matrix, genes were        
selected for dimensionality reduction with a minimum expression of 3 UMIs in at least 1% of all                 
cells. From those, the top 30% of genes with the highest coefficient of variation were selected.                
Dimensionality reduction was performed in two steps, first with a principal component analysis             
(PCA) using the most variable genes and the R package ​irlba v2.3.3 ​104​, then using the first 7 PCs                   
(>90% of the variance explained) as input to a t-distributed stochastic neighbor embedding             
(tSNE; package ​Rtsne v0.15) with parameters ​perplexity = 30, check_duplicates = F, pca = F ​105​.                
Clusters were defined on the resulting tSNE 2-dimensional embedding, using the density peak             
algorithm ​106 implemented in ​densityClust v0.3 and selecting the top cluster centers based on the               
𝛾 value distribution (​𝛾 = ​𝜌✕ 𝛿​; ​𝜌 = local density; ​𝛿 = distance from points of higher density). Using                     
known cell type markers, clusters that corresponded to erythrocytes or potential cell doublets             
were excluded and the remaining cluster were used to define 5 broad populations (Immune,              
Vascular, Astrocytes, Oligodendrocytes and Neuronal). Erythrocyte marker genes (​Hba-a1 ​,         
Hba-a2 ​, ​Hbb-b1 ​, ​Hbb-bh1 ​, ​Hbb-bh2 ​, ​Hbb-bs​, ​Hbb-bt ​, ​Hbb-y​, ​Hbq1a​, ​Hbq1b​) were excluded from            
the resulting expression matrix. Raw UMI counts were normalized separately for each batch of              
libraries (Table S3), using the function ​computeSumFactors ​from the package ​scran v1.12.1 ​107​,             
and parameter ​min.mean was set to select only the top 20% expressed genes to estimate size                
factors, using the 5 broad populations defined above as input to the parameter ​clusters​. After               
normalization, only cells with size factors that differed from the mean by less than one order of                 
magnitude were kept for further analysis (0.1x(𝜮(𝜃/N)) > 𝜃 > 10x(𝜮(𝜃/N)); 𝜃 = cell size factor; N                 
= number of cells). The normalized expression matrix was used in a second round of               
dimensionality reduction and clustering. The top 20% variable genes were selected as described             
above, and a mutual nearest neighbor approach was used to correct for batch effects              
implemented in the ​fastMNN function of package ​batchelor v1.0.1 ​108​. To determine the number              
of dimensions used in the batch correction, the top 12 PCs that explained 90% of the variance                 
were selected. The batch corrected embedding was used as input to tSNE, and the resulting 2D                
embedding was used to determine clusters as described above. Marker genes for each cluster              
were identified by a differential expression analysis between each cluster and all other cells,              
using ​edgeR ​109​, with size factors estimated by ​scran and including the batch information in the                
design model. Known cell type markers were used to determine 7 main populations (Immune,              
Endothelial, Pericytes, Ependymal, Astrocytes, Neuronal and Oligodendrocytes/OPCs). Each of         
these populations was independently re-clustered following the same procedure described          
above, to reveal more specific cell types and remove potential cell doublets (Figure S1). All R                
scripts for the steps described here are available through GitHub          
(github.com/elisadonnard/FXSinDrop). 
Differential expression and GSEA analysis 
Differentially expressed (DE) genes between genotypes were identified per cell type using            
edgeR ​, with size factors estimated by ​scran and including the batch information in the design               
model. Only genes that had at least one UMI in 15% of the cells of that type were used in the                     
analysis. Genes were considered DE when they showed an FDR<0.01 and at least 1.15x fold               
change. Complete DE results can be found in Table S1. 
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 The gene set enrichment analysis (GSEA v3.0) ​110 was performed using a ranked gene list               
constructed from the ​edgeR result. Genes were ranked by their reported fold change (logFC).              
GSEA was run via command line with parameters ​--set_max 3000 -set_min 30 ​. The reference of               
GO term annotations for mouse Entrez GeneIDs was obtained from the ​org.Mm.eg.db package             
v3.8.2. GO terms were considered significantly altered if they showed an FDR<0.01. A total of               
863 Gene Ontology (GO) terms had significant alteration (FDR<0.01) in one or more cell types.               
GO terms with high similarity were collapsed into 538 non-redundant categories           
(collapsedNAME, Table S2), using the function ​plot_go_heatmap from the package          
SignallingSingleCell​, which compares the leading edge list of genes for each enriched pathway             
and creates a unified term if the overlap is greater than 80%. Collapsed categories were used to                 
compare the results from different cell types (Figures 2a-b, S2c-d). 
FMRP bound mRNA expression analysis 
The normalized expression matrix was subset to select only WT cells and FMRP-bound mRNAs              
defined by Darnell ​et al. ​72 expressed by at least one cell (n=743). Cells were ordered first based                  
on cell type assignment and hierarchically clustered based on the expression of these mRNAs              
(​dist function ​method=”euclidian”​; ​hclust function ​method=”average”​). Genes were clustered         
using ​k-means (k=7) followed by hierarchical clustering within the k-means cluster. Resulting            
clusters were merged based on the cell type pattern of expression to obtain the final three                
clusters (Neuronal, Non-neuronal, Non-specific). 
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